• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

171179-06-9 (N4-(3-Bromophenyl)-N6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine)

1

Identification

N4-(3-Bromophenyl)-N6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine N4-(3-Bromophenyl)-N6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine
Name N4-(3-Bromophenyl)-N6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine
Formula C14H12BrN5
MW 330.18
CAS No. 171179-06-9
EINECS
Smiles CNC1=CC(C(NC2=CC(Br)=CC=C2)=NC=N3)=C3C=N1
Synonyms N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine
InChI InChI=1S/C14H12BrN5/c1-16-13-6-11-12(7-17-13)18-8-19-14(11)20-10-4-2-3-9(15)5-10/h2-8H,1H3,(H,16,17)(H,18,19,20)
2

Introduction

Background Information

PD158780 is a very potent inhibitor of EGFR with IC50 of 0.08 nM; pan-specific antagonist of ErbB receptor. IC50 value: 0.08 nM [1] Target: EGFR inhibitor in vitro: PD158780 potently inhibited the LPA-stimulated MAP kinase kinase 1/2 (MKK1/2) activation and EGF receptor tyrosine phosphorylation in HeLa cells, while it had no detectable effect on c-Src kinase activity. PD158780 also inhibited LPA-induced MKK1/2 activation and DNA synthesis in NIH 3T3 cells. Furthermore, we compared LPA-stimulated MKK1/2 and MAP kinase activation, transcriptional activity of the c-fos promoter, and DNA synthesis in B82L cells, which lack endogenous EGF receptor, and B82L cells expressing kinase-defective or wild-type human EGF receptor [2]. in vivo: NRG-1beta dramatically increases gamma oscillation power in hippocampal slices from both rats (2062 +/- 496%) and mice (710 +/- 299%). These effects of NRG-1beta are blocked by PD158780, a pan-specific antagonist of ErbB receptors, and are mediated specifically via ErbB4 receptors, because mice harboring a targeted mutation of ErbB4 do not respond to NRG-1 [3]. ......by MedChemexpress Co., Ltd.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance:Light yellow to yellow Solid EBNumber:EB000058036

Storage condition

4°C by MedChemexpress Co., Ltd.

Solubility

DMSO 42 mg/ml by CHEMSCENE, LLC
DMSO 42 mg/ml by MedChemexpress Co., Ltd.
5

Mechanism and Indication

Signaling Pathways JAK/STAT Signaling Protein Tyrosine Kinase/RTK
Target EGFR
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
N4-(3-Bromophenyl)-N6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine - No Development Reported
7

Safety Data of N4-(3-Bromophenyl)-N6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine

Hazard Symbols : Xn
Risk Statements : R22
8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
Abcam 10mg/USD140();50mg/USD558() USA
CHEMSCENE, LLC USA
Cayman Chemical Company 1mg/USD29() USA
EMD Millipore USA
MedChemexpress Co., Ltd. 10mg/USD135(In stock);50mg/USD588(In stock) USA
Santa Cruz Biotechnology, Inc. 10mg/USD169() USA
Shanghai Haoyuan Chemexpress Co., Ltd. China
Shanghai MOF Chemical Tech Limited China
Tocris Bioscience Inc. 10mg/USD179() USA
10

Related Products

Other Forms of 171179-06-9

Name CAS No Formula MW

Recommended Compounds in EGFR

Name CAS No Formula MW
Ginsenoside Rh2 78214-33-2 C36H62O8 622.87
Mutated EGFR-IN-1 1421372-66-8 C25H31N7O 445.56
AZD-9291 (mesylate) 1421373-66-1 C29H37N7O5S 595.71
Mutant EGFR inhibitor 1421373-62-7 C27H30ClN7O2 520.03
AZD-9291 1421373-65-0 C28H33N7O2 499.61
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
WHI-P180 211555-08-7 C16H15N3O3 297.31
Gefitinib (hydrochloride) 184475-55-6 C22H25Cl2FN4O3 483.36
Erlotinib (mesylate) 248594-19-6 C23H27N3O7S 489.54
BGB-102 807640-87-5 C22H25BrN4O2 457.36
Poziotinib 1092364-38-9 C23H21Cl2FN4O3 491.34
CO-1686 (hydrobromide) 1446700-26-0 C27H29BrF3N7O3 636.46
CO-1686 1374640-70-6 C27H28F3N7O3 555.55
CNX-2006 1375465-09-0 C26H27F4N7O2 545.53
PD 168393 194423-15-9 C17H13BrN4O 369.22
AG 18 118409-57-7 C10H6N2O2 186.17
Afatinib (dimaleate) 850140-73-7 C32H33ClFN5O11 718.08
Chrysophanic acid 481-74-3 C15H10O4 254.24
AG-1478 153436-53-4 C16H14ClN3O2 315.75
Mubritinib 366017-09-6 C25H23F3N4O2 468.47

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

N4-(3-Bromophenyl)-N6-methyl-pyrido[3,4-d]pyrimidine-4,6-diamine

Tags: buy 171179-06-9 IC50 | 171179-06-9 price | 171179-06-9 cost | 171179-06-9 solubility | 171179-06-9 purchase | 171179-06-9 manufacturer | 171179-06-9 research buy | 171179-06-9 order | 171179-06-9 MSDS | 171179-06-9 chemical structure | 171179-06-9 Storage condition | 171179-06-9 molecular weight | 171179-06-9 mw | 171179-06-9 datasheet | 171179-06-9 supplier | 171179-06-9 cell line | 171179-06-9 NMR | 171179-06-9 MS | 171179-06-9 IR | 171179-06-9 solubility | 171179-06-9 Safe information | 171179-06-9 Qc and Spectral Information | 171179-06-9 Clinical Information | 171179-06-9 Clinical Trial | 171179-06-9 Route of Synthesis | 171179-06-9 storage condition | 171179-06-9 diseases and conditions | 171179-06-9 flash point | 171179-06-9 boiling point | 171179-06-9 melting point | 171179-06-9 storage condition | 171179-06-9 brand